Experimental GLS1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer
UT MD Anderson News Release November 18, 2026
- A subset of platinum-resistant ovarian cancers become highly dependent on glutamine when treated with the standard of care
- Broadly inhibiting the enzymes that provide access to glutamine, GLS1 and GLS2 has previously failed and comes with unwanted side effects
- IACS-6274 is an experimental oral medication developed at UT MD Anderson that selectively targets only GLS1 and is better absorbed
- In this Phase 1 trial of 14 patients, nine confirmed partial responses of at least 30% shrinkage in tumor size and three had stable disease
- ·These results led to expansion of the Phase 1 trial, which is also investigating IACS-6274 in other cancer types and combinations
Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase 1 trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of Texas MD Anderson Cancer Center.
IACS-6274 is a targeted therapy developed by UT MD Anderson’s Therapeutics Discovery division that is designed to block a key metabolic enzyme. The data were presented today at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics by principal investigator Timothy Yap, M.B.B.S, Ph.D., professor of Investigational Cancer Therapeutics and head of clinical development in UT MD Anderson’s Therapeutics Discovery division.
“We saw deep and durable responses in these patients with advanced, hard-to-treat ovarian cancer,” Yap said. “In 10 patients who either had a partial response or had stable disease, the responses lasted at least four months, with some lasting nearly three years. This is a meaningful difference for these patients, who currently do not have any good options once their disease reaches this stage.”
What were the key results of the IACS-6274 trial?
The Phase 1 trial included 13 patients whose ovarian cancers did not respond to platinum-based therapies. All patients’ tumors had stopped responding to standard-of-care treatment.
Of the 13 patients evaluable for efficacy, nine had confirmed partial responses, with their tumors shrinking by at least 30%. Three patients had stable disease, meaning their cancers neither grew nor shrank. Eleven of the 13 patients had disease control 12 weeks after the start of the trial.
The therapy was well-tolerated, with no dose-limiting toxicities. Adverse effects were mostly mild nausea, fatigue, hair loss, anemia, nose bleeds, elevated liver enzymes, neutropenia, and nail and vision disturbances. More severe side effects included higher grade neutropenia, elevated blood pressure and anemia, but they were successfully treated.
How does IACS-6274 work?
About a quarter of all ovarian cancers are initially resistant to platinum-based chemotherapy, and an even larger number eventually develop resistance to the treatment. For either set of patients, the standard of care is a combination of the chemotherapy paclitaxel and the VEGF inhibitor bevacizumab.
Most cancers will develop resistance to this combination within a year by becoming overly dependent on a nutrient called glutamine. Scientists have theorized that inhibiting glutamine could overcome resistance, but broad inhibition in previous trials resulted in dose-limiting side effects.
IACS-6274 was developed to inhibit glutaminase-1 (GLS-1), which can block the ability of these cancers to access glutamine. Importantly, it does so without affecting glutaminase-2, an important enzyme in several biological processes. That selectivity is where many previous attempts at GLS inhibition failed.
Additionally, IACS-6274 was designed to be better absorbed than previous GLS inhibitors. Modern genetic testing has also uncovered a subset of cancers that lack an enzyme called ASNS, which means they are completely dependent on glutamine for survival and are more likely to benefit from this treatment. Eight of the 14 patients on this trial had ASNS loss, with six of them being partial responders.
What’s next for IACS-6274?
Based on these data, 15 additional patients will be treated with the combination on the trial, with further expansion planned with an additional 15 patients if the results continue to be positive.
“This is really an exciting trial for us because it’s a perfect example of our ability to develop a therapy that addresses a need we see in the clinic,” said Tim Heffernan, Ph.D., vice president and head of research and development in UT MD Anderson’s Therapeutics Discovery Division. “It’s also an example of how the trial data feeds back into our research to continue to better select patients who could benefit from this therapy.”
***
This trial is supported by UT MD Anderson. A full list of authors and their disclosures can be found with the abstract.
This is a meaningful difference for these patients, who currently do not have any good options once their disease reaches this stage.